Lupin launches cardiovascular drug in US market

Lupin :  It launched generic heart rivaroxaban tablets in the US market after it received approval from the US Food and Drug Administration (US FDA).

According to the company, the Rivaroxaban Tablets USP, 2.5 mg tablets are a bioequivalent of Janssen Pharmaceuticals’ Xarelto® Tablets, 2.5 mg, which generated an estimated $446 million in sales annually in the US.

Shares of Lupin closed at Rs 2,029.00, up 0.52% on the National Stock Exchange (NSE). However, it announced the new drug launch after market hours.

The newly launched drug will be used to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD). Additionally, it will help “to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularisation due to symptomatic PAD,” the company said in a regulatory filing.

Lupin share performance

Lupin shares gained 6.58% over the week but have lost 8.45% since the beginning of February. The script has fallen 13.83% on a year-to-date basis.

It hit its 52-week high of Rs 2,402.90 on January 2, 2025 and low of Rs 1,493.30 on June 4, 2024

The pharmaceutical company has a total market cap of Rs 92,632.16 crore as of March 7, 2025, on the NSE.

About Lupin

Headquartered in Mumbai, Lupin is a global pharmaceutical company with operations spread across 100 markets. It specialises in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients.

Related Posts

  • Pharma
  • August 8, 2025
  • 466 views
Delhi Police busts major fake medicine racket; 6 arrested including kingpin

The Anti-Gang Squad of the Crime Branch of Delhi Police has busted a major interstate racket involved in the manufacturing, selling, and supplying of counterfeit lifesaving medicines. In this significant…

  • Pharma
  • August 8, 2025
  • 262 views
Indian Pharma Market grows by 7.9% in July; antibiotic Augmentin rebounds to top spot

New Delhi: The Indian Pharmaceutical Market (IPM) in July underwent a value growth of 7.9 per cent driven by new launches in the anti-diabetic segment and value growth of cardiac…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Govt Temporarily Eases BIS Rules for Medical Device Parts

Biocon Bets Big on Insulin, Eyes GLP-1 Drugs for Future Growth

Biocon Bets Big on Insulin, Eyes GLP-1 Drugs for Future Growth

Delhi Police busts major fake medicine racket; 6 arrested including kingpin

Delhi Police busts major fake medicine racket; 6 arrested including kingpin

Indian Pharma Market grows by 7.9% in July; antibiotic Augmentin rebounds to top spot

Indian Pharma Market grows by 7.9% in July; antibiotic Augmentin rebounds to top spot